Taipei, Taiwan, January 10, 2024 — Taipei, Taiwan, January 10, 2024 - Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, today reported its unaudited consolidated revenue for 2024, reaching an all-time high of NT$18.6 billion, with a 10% year-over-year (YoY) increase.
In December 2024, the company achieved unaudited consolidated revenue of NT$1,463 million, marking a significant 38% month-over-month (MoM) and 7% YoY growth.
The fourth quarter of 2024 saw a strong revenue performance of NT$4.4 billion, representing a 29% YoY increase. This growth was driven by a surge in export revenue, which rose by over 60% YoY, fueled by strong demand for lenalidomide in the US market and oncology products globally. Additionally, revenue from Asia increased by 10% YoY, led by Thailand, which saw more than 450% YoY growth due to the integration of Lotus and Teva Pharma Thailand portfolios.
For the full year, export revenue and Asia revenue grew by 15% and 4% YoY, respectively.
In 2024, Lotus Pharmaceutical accelerated its strategic expansion in Southeast Asia, solidifying its leadership position in the region. The company successfully integrated Teva Pharma Thailand in August, strengthening its distribution channels across hospitals and pharmacies. Furthermore, Lotus completed its acquisition of Alphachymotrypsine Choay® in Vietnam ahead of schedule, with sales expected to be recognized starting in the first quarter of 2025. In 2023, Alphachymotrypsine Choay® generated annual sales of US$22 million across Vietnam and Cambodia.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on delivering novel and generic medicines that are safer, better, and more accessible. With a best-in-class R&D and manufacturing platform in Asia, Lotus has partnerships in key markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in development and registration across Asia and the U.S., with a portfolio of more than 250 commercial products. Lotus invests in a diversified pipeline of high-barrier oncology treatments, complex generics, 505(b)2 products, and new chemical entities (NCEs), through internal R&D and licensing partnerships. Additionally, it bolsters its portfolio with biosimilars, supported by strategic alliances. Lotus's facilities are certified by top regulatory bodies, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com